Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170865 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL251553 | 0.95 | CNR1 (0.46) | ALDH1A1CNR1CNR2 | |
| SCHEMBL251555 | 0.95 | CNR1 (0.46) | ALDH1A1CNR1CNR2 | |
| SCHEMBL27320 | 0.91 | ALDH1A1 (0.43) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1921025 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL5561906 | 0.86 | SPHK1 (0.43) | — | |
| SCHEMBL251629 | 0.86 | SPHK1 (0.43) | — | |
| SCHEMBL30290989 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15018073 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15018493 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094668-A | Preparation method and application of lipid nanoparticle | — | 2026-05-26 | — | — | CN | claimed |
| EP-3201338-B1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | ARBUTUS BIOPHARMA CORP (CA) | 2021-11-03 | — | — | EP | claimed |
| US-20210284733-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-09-16 | — | — | US | claimed |
| US-20200385721-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-10 | — | — | US | claimed |
| US-10626393-B2 | Delivering CRISPR therapeutics with lipid nanoparticles | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-04-21 | — | — | US | claimed |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2019-11-07 | — | — | US | claimed |
| US-20190328664-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-31 | — | — | US | claimed |
| US-10415037-B2 | Compositions and methods for silencing hepatitis B virus gene expression | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-09-17 | — | — | US | claimed |
| US-20190032051-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2019-01-31 | — | — | US | claimed |
| US-20180245077-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-08-30 | — | — | US | claimed |
| US-20160076035-A1 | COMPOSITIONS AND METHODS FOR SILENCING MARBURG VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-03-17 | — | — | US | claimed |
| US-20160032320-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2016-02-04 | — | — | US | claimed |
| US-20140248338-A1 | COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-09-04 | — | — | US | claimed |
| US-8716464-B2 | Compositions and methods for silencing Ebola virus gene expression | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-05-06 | — | — | US | claimed |
| US-20130172405-A1 | COMPOSITIONS AND METHODS FOR SILENCING SMAD4 | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-07-04 | — | — | US | claimed |
| US-20130122104-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | claimed |
| US-8283333-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-10-09 | — | — | US | claimed |
| US-20110313017-A1 | SNALP FORMULATIONS CONTAINING POLYOXAZOLINE-DIALKYLOXYPROPYL CONJUGATES | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-12-22 | — | — | US | claimed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | claimed |
| WO-2011011447-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | ALDH1A1 2057/4885CNR1 3865/4885CNR2 4215/4885 |
| US-20210284733-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | CD274, PDCD1, HAVCR2 | ALDH1A1 260/4885CNR1 3309/4885CNR2 4382/4885 |
| US-20190032051-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885CNR1 4202/4885CNR2 4528/4885 |
| US-20180245077-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | APOB, APOL1, LPL | ALDH1A1 4258/4885CNR1 4611/4885CNR2 4656/4885 |
| US-10415037-B2 | Compositions and methods for silencing hepatitis B virus gene expression | HAVCR2, HDGF, LDLR | ALDH1A1 4150/4885CNR1 3305/4885CNR2 3843/4885 |
| US-20140248338-A1 | COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE | ALDH2, ADH1A, ALDH3A1 | ALDH1A1 6/4885CNR1 3088/4885CNR2 3455/4885 |
| US-20160076035-A1 | COMPOSITIONS AND METHODS FOR SILENCING MARBURG VIRUS GENE EXPRESSION | PLIN3, PLIN1, PLIN5 | ALDH1A1 3280/4885CNR1 4121/4885CNR2 4502/4885 |
| US-20110313017-A1 | SNALP FORMULATIONS CONTAINING POLYOXAZOLINE-DIALKYLOXYPROPYL CONJUGATES | DAZAP1, SPOP, PNKP | ALDH1A1 1532/4885CNR1 4495/4885CNR2 4648/4885 |
| US-20190328664-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | IL2, CD47, IL5 | ALDH1A1 1351/4885CNR1 783/4885CNR2 347/4885 |
| US-20160032320-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885CNR1 4202/4885CNR2 4528/4885 |
| US-20200385721-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | LDLR, SREBF2, NPC1 | ALDH1A1 1652/4885CNR1 3258/4885CNR2 3809/4885 |
| US-10626393-B2 | Delivering CRISPR therapeutics with lipid nanoparticles | LDLR, SREBF2, NPC1 | ALDH1A1 1652/4885CNR1 3258/4885CNR2 3809/4885 |
| US-20130122104-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | ALDH1A1 2057/4885CNR1 3865/4885CNR2 4215/4885 |
| US-20130172405-A1 | COMPOSITIONS AND METHODS FOR SILENCING SMAD4 | LDLR, SMAD3, AGO2 | ALDH1A1 4490/4885CNR1 4172/4885CNR2 4285/4885 |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | PHAX, LNPEP, PITPNB | ALDH1A1 4507/4885CNR1 4628/4885CNR2 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.